Immunotherapies in Combination with Radiation Therapy: Optimal Study Design - AM2019
This workshop was developed in collaboration between ASTRO and Society for Immunotherapy of Cancer (SITC). The workshop provides examples of different settings and study design to test currently available commercial immunotherapies combined with radiation therapy. The session will be limited to immunotherapies in clinical use and we will not discuss experimental drugs or mechanisms. We will first provide a brief introduction on the diversity of the mechanisms of resistance to current ICB. Three examples of original ongoing clinical trials will be presented, on the neoadjuvant, adjuvant and selected metastatic setting. This course will be especially useful for community and academic clinicians interested in designing novel clinical trials.
The activity is designed to meet the interests of medical oncologists, radiation oncologists, nurses, and residents.
- Distinguish the diversity of the mechanisms of immune resistance and evasion in cancer.
- Identify the variety of opportunities associated with distinct clinical settings to test the combination of RT and ICB.
- Explore examples of currently ongoing trials of radiation combined with ICB.
The following persons served as faculty for this activity:
Sandra Demaria, MD is employed at Weill Cornell Medical College and receives compensation/remuneration/funding from EMD Serono, Lytix Biopharma, Mersana Therapeutics and Nanobiotix.
Jonathan P.S. Knisely, MD, FASTRO is employed at Weill Cornell Medical College and has nothing to disclose.
Sana Karam MD, PhD is employed at the University of Colorado Cancer Center and has nothing to disclose.
Manisha Palta, MD is employed at Duke University and receives compensation/remuneration/funding from Merck and Varian.
Additionally, the Education and CME/MOC Committees had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
- 1.25 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.25 self-assessment credits.
- No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
- No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
- ASTRO staff cannot make modifications to your submitted materials.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.